-
ALSO READ
DRL stock falls 10% after missing Q1 estimates, probe by US SEC
Jubilant FoodWorks rallies 25% in three weeks; hits new high on BSE
DRL plans to start paediatric trials of Sputnik Light vaccine soon
DRL launches DRDO drug 2-DG to treat moderate to severe Covid patients
Steps to undertake while conducting a mid-year review of your portfolio
-
Dr Reddy’s Laboratories (DRL) is working on several product extensions as well as market expansions for its Covid products portfolio. For example, it is working on bringing in a 1 ml liquid intravenous injectable version of Gilead’s remdesivir, a drug widely used for Covid patients with moderate to severe symptoms.
Similarly, for its oral antiviral drug favipiravir, which it sells under an agreement with Japanese innovator FujiFilm, it is looking to expand markets beyond India, the company said.
As for MSD’s drug Molnupiravir, which is currently undergoing clinical trial in India, the company said it has already shared interim data with the drug regulator.
DRL is also trying to have label expansion for mild patients for the 2-DG or 2-Deoxy-d-Glucose that it developed with the Institute of Nuclear Medicine & Allied Sciences, a Defence Research and Development Organisation arm.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU